tiprankstipranks
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Income Statement

1,233 Followers

Citius Pharmaceuticals Income Statement

Last quarter (Q4 2023), Citius Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Citius Pharmaceuticals's net income was $-9.23M. See Citius Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
--$ 90.00K$ 90.00K$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
--$ 90.00K$ 90.00K--
Operating Expense
$ 38.82M$ 36.73M$ 33.32M$ 23.53M$ 17.71M$ 15.60M
Operating Income
$ -38.82M$ -36.73M$ -33.32M$ -23.53M$ -17.71M$ -15.60M
Net Non Operating Interest Income Expense
$ 1.22M$ 1.18M$ 251.40K$ 250.99K$ 52.39K$ 36.22K
Other Income Expense
-$ -3.59M-$ -226.47K$ 110.21K-
Pretax Income
$ -37.60M$ -31.97M$ -33.06M$ -23.05M$ -17.55M$ -15.56M
Tax Provision
$ 576.00K$ 576.00K$ 576.00K$ -1.23K$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -39.33M$ -33.69M$ -33.64M$ -23.05M$ -17.55M$ -15.56M
Basic EPS
$ -0.25$ -0.22$ -0.23$ -0.23$ -0.45$ -0.77
Diluted EPS
$ -0.25$ -0.22$ -0.23$ -0.23$ -0.45$ -0.77
Basic Average Shares
$ 617.92M$ 151.29M$ 146.08M$ 108.60M$ 39.17M$ 20.16M
Diluted Average Shares
$ 617.92M$ 151.29M$ 146.08M$ 108.60M$ 39.17M$ 20.16M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 38.82M$ 36.73M$ 33.32M$ 23.53M$ 17.71M$ 15.60M
Net Income From Continuing And Discontinued Operation
$ -38.18M$ -32.54M$ -33.64M$ -23.05M$ -17.55M$ -15.56M
Normalized Income
$ -23.32M$ -25.25M--$ -17.55M$ -15.56M
Interest Expense
----$ 15.67K$ 16.44K
EBIT
$ -37.60M$ -31.97M$ -33.06M$ -23.04M$ -17.53M$ -15.55M
EBITDA
$ -37.41M$ -31.77M$ -32.88M$ -22.88M$ -17.38M$ -15.54M
Currency in USD

Citius Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis